Evidence map›Paper›PMID 35328264›Full record

ArticleDiagnostics (Basel, Switzerland)2022

Use of a FluoroType

Anna Zabost, Dorota Filipczak, Włodzimierz Kupis, Monika Szturmowicz, Łukasz Olendrzyński, Agnieszka Winiarska, Jacek Jagodziński, Ewa Augustynowicz-Kopeć

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anna ZabostDepartment of Microbiology, National Tuberculosis and Lung Diseases Research Institute, 01-138 Warsaw, Poland.ORCID 0000-0003-2781-9844
Dorota FilipczakDepartment of Microbiology, National Tuberculosis and Lung Diseases Research Institute, 01-138 Warsaw, Poland.
Włodzimierz KupisDepartment of Thoracic Surgery, National Tuberculosis and Lung Diseases Research Institute, 01-138 Warsaw, Poland.
Monika Szturmowicz1st Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, 01-138 Warsaw, Poland.
Łukasz OlendrzyńskiSTOCER Mazovian Rehabilitation Center, Dr. Włodzimierz Roefler Memorial Hospital of the Polish Railroads, 05-800 Pruszków, Poland.
Agnieszka WiniarskaDepartment of Radiology, National Tuberculosis and Lung Diseases Research Institute, 01-138 Warsaw, Poland.
Jacek JagodzińskiX Department of Lung Diseases and Tuberculosis, Mazovian Centre of Lung Diseases and Tuberculosis, 05-400 Otwock, Poland.
Ewa Augustynowicz-KopećDepartment of Microbiology, National Tuberculosis and Lung Diseases Research Institute, 01-138 Warsaw, Poland.ORCID 0000-0001-6162-8748

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

According to the World Health Organization (WHO), there were 465,000 cases of tuberculosis caused by strains resistant to at least two first-line anti-tuberculosis drugs: rifampicin and isoniazid (MDR-TB). In light of the growing problem of drug resistance in

Indexed as

drug resistanceFluoroType MTBDRisoniazidmolecularMycobacterium tuberculosisrifampintuberculosis

Identifiers

PMID35328264
PMCPMC8947722
OpenAlexW4220921911

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.